In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $31.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight the potential of Liquidia Technologies. Firstly, Yutrepia, Liquidia’s lead asset for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), stands out due to its unique PRINT technology. This allows for more precise particle manufacturing, resulting in better lung delivery and potentially higher, more tolerable dosing compared to existing inhaled prostacyclin products.
Another critical factor supporting the Buy rating is the positive interim data from the ASCENT trial. The trial demonstrated strong tolerability with no dropouts among participants, allowing patients to achieve significantly higher doses than those of a competing product. Additionally, the resolution of legal issues with United Therapeutics, particularly the invalidation of a key patent, positions Liquidia favorably for a successful launch. These elements collectively suggest promising commercial prospects for Liquidia’s Yutrepia, thus justifying the Buy recommendation.
In another report released on January 30, Scotiabank also maintained a Buy rating on the stock with a $30.00 price target.